Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Hepatology. 2023 Jan 3;77(6):1983–1997. doi: 10.1097/HEP.0000000000000024

FIGURE 3.

FIGURE 3

Activation of RNA Pol III promotes RNA5SP expression. (A) Expression of the components of RNA Pol III machinery, represented by TPMs from GSE143318. (B) Western blot of MAF1 expression in healthy control and sAH livers. (C) Quantification of the western blot in using ImageJ. (D) Immunohistochemistry of hepatic MAF1 expression. Red arrows: Nuclear staining of MAF1 in parenchymal cells; black arrows: in nonparenchymal cells. (E) Quantitative PCR of 5S rRNA expression. (F) Expression of RNA5SP transcripts was increased by poly (I:C). THP-1 cells were transfected with poly (I:C) for 24 hours, and gene expression was determined by quantitative PCR. (G) The Pol III inhibitor, ML60218, inhibited poly (I:C)-induced RNA5SP expression. (F and G): Data are mean ± SEM of 3 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. (G): Only comparisons made were between poly (I:C) DMSO versus poly (I:C) ML60218. Abbreviations: Pol III, RNA polymerase III; sAH, severe alcohol-associated hepatitis; TPM, transcripts per million.